Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
An Open-Label Randomized Pilot Study of Safety and Preliminary Efficacy of TG100801 in Patients With Choroidal Neovascularization Due to Age-Related Macular Degeneration
Sponsor: TargeGen
Terminated
This trial was terminated. No reason was provided.
Other Choroidal Neovascularization trials with similar outcome
A PHASE2 clinical study on Choroidal Neovascularization and Macular Degeneration, this trial is terminated or withdrawn. The trial is conducted by TargeGen and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TargeGen
For direct contact, visit the study record on ClinicalTrials.gov .